Adding nevirapine to drugs given newborns of women diagnosed with HIV shortly before or during labor halves the newborns' risk of HIV, U.S. researchers say. Study author Dr. Heather Watts of the Eunice Kennedy Shriver National Institute of Child Health and Human Development said the rate of mother-to-child HIV transmission around the time of delivery was 2.2 percent among infants who received the standard drug zidovudine combined with nevirapine, compared with 4.8 percent among infants treated with zidovudine alone. The study, which involved 1,600 infants, found a reduced rate of transmission -- 2.4 percent -- among infants treated with a three-drug combination: zidovudine, nelfinavir and lamivudine. However, infants given the two-drug combination were less likely than were those on the three drug regimen to have neutropenia -- a blood disorder consisting of low levels of neutrophils, a type of infection-fighting white blood cells. "Pregnant women who don't know they have HIV or those who don't come in for prenatal care may not get the early treatment needed to keep the virus from being passed on to the baby," Watts said in a statement. "Our findings show that even in these situations, many, many infant cases of HIV can be prevented with the two drug combination treatment." The findings were published in the New England Journal of Medicine.
GMT 18:35 2018 Thursday ,11 January
Syrian refugee sets himself ablaze at UN office in LebanonGMT 18:48 2018 Tuesday ,09 January
Novo Nordisk woos Belgian nano-drug makerGMT 17:54 2017 Wednesday ,27 December
Medical evacuations begin from besieged Syria rebel bastionGMT 12:14 2017 Monday ,25 December
MoHAP successfully conducts cochlear implant operationGMT 18:24 2017 Sunday ,24 December
Palestinian conjoined twins arrive in RiyadhGMT 19:05 2017 Monday ,18 December
new! magazine names fitness & food editorGMT 17:03 2017 Wednesday ,29 November
Spain reports case of 'mad cow disease'GMT 14:05 2017 Saturday ,11 November
EU can't agree on new licence for controversial glyphosate weedkiller
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor